← Leaderboards
Mark Allen Jensen
Iterative Therapeutics, Inc.
$500,128
Attributed
$500,128
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $269.1K · FY2010–11$500K$375K$250K$125K$0
'10
'11
Funding mix
By agency
NIH$500,128 · 1
By mechanism
R43$500,128 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Affinity”
- Dennis R. Burton · Scripps Research Institute$64,397,776
- James E Crowe · Vanderbilt University Medical Center$53,471,415
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$45,445,140
- Timothy A Springer · Boston Children'S Hospital$41,593,445
- Misty Ward Stevens · Intervexion Therapeutics, Llc$38,187,594
- Rafi Ahmed · Emory University$36,776,987
Research focus
AffinityAnalogAngiogenic FactorAntibodiesAntibody -Dependent Cell CytotoxicityAvidityBinding (Molecular Function)Cancer PatientCancer TherapyCell Cycle ProgressionCell GrowthCell KillingCell ProliferationCellsCell SurfaceCloningCrosslinkDown-RegulationErbb2 GeneFailure (Biologic Function)Fda ApprovedGlycocalyxGrowthActivated Natural Killer Cell